Literature DB >> 1384112

Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up.

M Yousuf1, Y Nakano, E Tanaka, T Sodeyama, K Kiyosawa.   

Abstract

To clarify the evolution of antibody to hepatitis C virus (anti-HCV) and of liver histologic findings during the natural course of type-C chronic hepatitis, 111 patients with biopsy-proven chronic hepatitis type C were consecutively enrolled in this study and were followed up biochemically, serologically, and histologically for more than 5 years. All were positive for the first- and second-generation antibody to HCV (anti-HCV-1 and anti-HCV-2). None received antiviral therapy during the follow-up period. At the end of follow-up, all remained positive for anti-HCV-2, but four patients turned negative for anti-HCV-1. HCV RNA, detected by the polymerase chain reaction method, was tested serially in 20 patients who persisted positive anti-HCV-1 and in 4 patients who lost anti-HCV-1. HCV RNA disappeared from only two patients, who lost anti-HCV-1 during the follow-up period. A normalization of the serum transaminase level was found in only two patients, who lost both anti-HCV-1 and HCV RNA. A repeat liver biopsy was performed in 62 patients with chronic hepatitis who were persistently positive for all HCV markers and in 4 patients who lost anti-HCV-1. Of the 62 patients who retained all HCV markers, 16 progressed to hepatocellular carcinoma, 6 to cirrhosis of the liver, and 1 had a normal liver, whereas the remaining 39 had chronic hepatitis. Two patients who lost both anti-HCV-1 and HCV RNA showed a normal liver. Of two patients who lost only anti-HCV-1 one progressed to hepatocellular carcinoma and one to chronic hepatitis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384112     DOI: 10.3109/00365529209011189

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report.

Authors:  Takumi Kawaguchi; Shuji Sumie; Minoru Itou; Eitaro Taniguchi; Tsunetaka Matoba; Michio Sata
Journal:  Dig Dis Sci       Date:  2008-07-26       Impact factor: 3.199

3.  Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C.

Authors:  M Okazaki; K Hino; K Fujii; N Kobayashi; K Okita
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation.

Authors:  Hidenari Nagai; Katsuhiko Matsumaru; Kazue Shiozawa; Kouichi Momiyama; Noritaka Wakui; Masao Shinohara; Manabu Watanabe; Koji Ishii; Hiroko Nonaka; Akira Hasegawa; Tatsuo Teramoto; Wataru Yamamuro; Yasukiyo Sumino; Kazumasa Miki
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

5.  Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

Authors:  A Matsumoto; E Tanaka; T Suzuki; H Ogata; K Kiyosawa
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

6.  Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Authors:  U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

7.  Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases.

Authors:  C J Healey; R W Chapman; K A Fleming
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

8.  Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Authors:  Uwe Siebert; Gaby Sroczynski; Pamela Aidelsburger; Siegbert Rossol; Jürgen Wasem; Michael P Manns; John G McHutchison; John B Wong
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Follow-up study of acute hepatitis C.

Authors:  D Tan; S W Im; W W Peng; M H Ng
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.